This chapter reviews and expands upon the current pharmaceutical strategies, specifically PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors and lipoprotein(a)-lowering RNA-based agents, with mechanistic insight drawn from recent advances in our understanding of calcific aortic valve stenosis progression—Table 1. This evidence concerns the gene PCSK9 and stricture.